GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pyxis Oncology Inc (NAS:PYXS) » Definitions » Other Stockholders Equity

PYXS (Pyxis Oncology) Other Stockholders Equity : $-0.00 Mil (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Pyxis Oncology Other Stockholders Equity?

Pyxis Oncology's Other Stockholders Equity for the quarter that ended in Jun. 2024 was $-0.00 Mil.

Pyxis Oncology's quarterly Other Stockholders Equity increased from Dec. 2023 ($-0.00 Mil) to Mar. 2024 ($0.00 Mil) but then declined from Mar. 2024 ($0.00 Mil) to Jun. 2024 ($-0.00 Mil).

Pyxis Oncology's annual Other Stockholders Equity stayed the same from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($0.00 Mil) but then declined from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($-0.00 Mil).


Pyxis Oncology Other Stockholders Equity Historical Data

The historical data trend for Pyxis Oncology's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pyxis Oncology Other Stockholders Equity Chart

Pyxis Oncology Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Other Stockholders Equity
- - - - -

Pyxis Oncology Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Pyxis Oncology Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity


Pyxis Oncology Other Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Pyxis Oncology's Other Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Pyxis Oncology Business Description

Traded in Other Exchanges
N/A
Address
321 Harrison Avenue, Boston, MA, USA, 02118
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.
Executives
Pamela Ann Connealy officer: Chief Financial Officer 320 W 37TH STREET, 3RD FLOOR, NEW YORK NY 10016
Jitendra Wadhane officer: Chief Accounting Officer 35 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140
Lara Sullivan director, officer: Chief Executive Officer C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD, SUITE 455, ROCKVILLE MD 20850
Jakob Dupont director C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Pfizer Inc 10 percent owner 66 HUDSON BOULEVARD EAST, NEW YORK NY 10001-2192
Pfizer Ventures (us) Llc 10 percent owner 66 HUDSON BOULEVARD EAST, NEW YORK NY 10001-2192
Rachel Humphrey director C/O MIRATI THERAPEUTICS INC., 4660 LA JOLLA VILLAGE DRIVE, SUITE 500, SAN DIEGO CA 92121
Plc Barclays 10 percent owner 1 CHURCHILL PLACE, CANARY WHARF, LONDON X0 E14 5HP
Mark Chin other: Former Director 20 BERKELEY SQUARE, MAYFAIR, LONDON X0 W1J 6EQ
Darren S Cline director 35 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140
Thomas Civik director C/O FOUNDATION MEDICINE, INC., 150 SECOND STREET, CAMBRIDGE MA 02141
Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Bayer World Investments B.v. 10 percent owner ENERGIEWEG 1, MIJDRECHT P7 3641
Freda C Lewis-hall director C/O VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY STREET, CAMBRIDGE MA 02139
Ronald Herbst officer: Chief Scientific Officer 35 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140